Hedgehog Pathway Inhibitor international drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes	8,178,563	⤷ Start Trial		Y		⤷ Start Trial
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes	8,063,043	⤷ Start Trial	Y	Y		⤷ Start Trial
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes	10,266,523	⤷ Start Trial	Y	Y		⤷ Start Trial
Genentech	ERIVEDGE	vismodegib	CAPSULE;ORAL	203388-001	Jan 30, 2012		RX	Yes	Yes	7,888,364	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 13, 2026

Hedgehog pathway inhibitors (HHIs) are a small, tightly patent-protected set centered on vismodegib (GDC-0449), sonidegib (LDE225), and itraconazole-based investigational repurposing in limited geographies, with additional smoothened-directed candidates in clinical development. Market dynamics are driven by (1) limited approved indications, (2) constrained safety/monitoring burden, (3) loss-of-exclusivity timing for early entrants, and (4) competitive pressure from newer SMO inhibitors with distinct dosing and tolerability profiles. The patent landscape is typically dominated by compound patents plus formulation, polymorph, and method-of-use claims tied to adult and pediatric tumor settings (notably basal cell carcinoma) and resistance biology. Generic entry risk varies sharply by product because FDA Orange Book coverage (where applicable), the breadth of claim sets, and the durability of infringement barriers (composition/formulation claims) differ by NDA.

Which Hedgehog pathway inhibitor drugs have the biggest patent estate, and when do they expire?

Short answer: The biggest patent estates in the HHI class sit with the earliest SMO inhibitors, where multiple layers (compound, polymorph/crystal form, formulation, and method-of-treatment) extend protection beyond the earliest patent grant. Expiration clustering is typically concentrated into mid-to-late 2020s, with the next wave dependent on Orange Book listings and any later patent grants or patent-term adjustments.

Core marketed SMO inhibitors that define the patent and market cycle

The HHI drug class market cycle is anchored by the following FDA-approved small-molecule SMO inhibitors:

Vismodegib (Erivedge; Genentech/Roche; NDA-holder activity is used in Orange Book listings)
Sonidegib (Odomzo; Novartis; Orange Book listings define legal barrier for generic entry)
Other Hedgehog-directed agents (mostly investigational or not first-line drivers for commercial cycle)

Market dynamics for these agents hinge on dermatology volumes, payer restrictions, and persistence risk from adverse events and discontinuations.

What claim layers are most common in HHI estates?

Patent estates for Hedgehog pathway inhibitors typically combine:

Composition of matter (SMO inhibitors, salt forms, and intermediates)
Polymorph/crystal form patents (including specific solid-state forms)
Formulation patents (tablet composition, excipient systems, particle size distribution)
Method-of-use patents (basal cell carcinoma subsets, neoadjuvant/adjuvant timing, dosing regimens)
Resistance or patient-selection patents (mutations in SMO, or biomarkers tied to response)

Expiration risk model (business framing)

For generic launch planning, the practical barrier is the number and proximity of Orange Book-listed patents to the proposed entry date and whether those patents are:

Mechanistic and broad (compound/method),
Narrow but hard to design around (polymorph or formulation),
Or litigation tested (if Paragraph IV has occurred and been resolved).

What patents protect vismodegib (Erivedge) and how strong is the estate?

Short answer: Vismodegib is protected by a layered estate that generally includes compound and additional patent families for specific solid-state/formulation and method-of-treatment coverage. The strength for generic entry depends on Orange Book-listed patents still in force and whether any are immune to typical design-around strategies.

Patent estate characteristics that control infringement risk

For vismodegib, infringement risk for an ANDA typically turns on:

Whether the generic must use the same active polymorph or equivalent solid form covered by claims.
Whether formulation patents cover specific tablet compositions and processing parameters.
Whether method-of-use claims narrow coverage to specific basal cell carcinoma settings.

Where market dynamics show up

Vismodegib’s commercialization is sensitive to:

Durability of dosing and discontinuation rates,
Competition from sonidegib and off-label alternatives,
Payer coverage decisions tied to response rates and tolerability.

If Orange Book coverage thins toward late 2020s, market share is exposed to earlier price compression for remaining labeled settings.

What patents protect sonidegib (Odomzo) and when does it lose exclusivity?

Short answer: Sonidegib has a layered patent estate in which compound and downstream formulation and method-of-use claims are the principal barriers to generic substitution. Loss of exclusivity timing hinges on the Orange Book patent list and the last-in-force patent family.

How do method-of-use and formulation claims affect generic entry?

For SMO inhibitors, generic ANDAs must avoid infringement on:

Method-of-treatment claims tied to basal cell carcinoma patient populations, and
Formulation/polymorph claims that can make “equivalent” product designs still infringing.

Market exposure drivers

Sonidegib’s market dynamics reflect:

Switch demand from prior SMO inhibitor failures,
Payer step edits based on prior therapy,
Safety management protocols that can slow adoption when adverse event burdens rise.

As the estate approaches expiry, expect:

Higher probability of Paragraph IV filings,
More intense price competition in existing formularies.

When do Hedgehog pathway inhibitor patents expire in the US, and what is the exclusivity timetable?

Short answer: The class-wide exclusivity timetable is constrained by the regulatory and patent system. For each SMO inhibitor NDA, the controlling date is the last Orange Book-listed patent expiration (not only initial filing), plus any pediatric exclusivity or non-patent exclusivities where applicable.

Typical US timing mechanics for this drug class

Compound patent earliest filing date plus patent term adjustments.
Orange Book listed patents that add years through formulation/polymorph and method families.
Regulatory exclusivities (if any) that can add a layer after patent expiry.
Paragraph IV window when the earliest date a generic can be filed is reached.

Practical “launch window” outcomes

If the last-in-force patent is a compound or method-of-use claim, design-around is difficult and launch is delayed until resolution.
If the last-in-force patent is a formulation/polymorph claim, a generic may pursue a different solid form or formulation, but that can become an expensive development and infringement risk exercise.
If claims are litigation-tested with a final court outcome, the market enters a more predictable launch pattern.

How many Orange Book patents cover Hedgehog pathway inhibitors, and which types dominate?

Short answer: In most SMO inhibitor NDAs, the Orange Book list includes multiple patents across different categories, with formulation/polymorph families often outnumbering single compound patents at later timepoints due to continuation practice.

Patent type distribution that matters commercially

For each drug, track:

Number of composition of matter patents
Number of formulation and polymorph patents
Number of method-of-use patents
Whether any are listed under “other” categories indicating non-obvious scope

Why coverage breadth drives pricing

More Orange Book patents near expiry increases settlement leverage for brand holders and increases generic entry costs.
Few near-expiry patents increases the likelihood of rapid generic adoption once the last remaining barrier resolves.

What Paragraph IV challenges and ANDA litigation has affected Hedgehog pathway inhibitors?

Short answer: HHI brands have faced periodic ANDA challenges as their exclusivity windows tighten. Litigation outcomes and settlements determine whether generics launch at entry-date risk or delay until claim expiry.

Litigation patterns common to this class

Brand holders assert multiple patents in a single infringement action.
Generic challengers may attack under “failure to state” or “invalidity/non-infringement.”
Settlement agreements often include delayed launch dates, design requirements, or carve-outs tied to patent expiry.

What to watch for in settlement terms

Launch delay measured from settlement effective date or from earliest court/administrative event.
Product design constraints around polymorph and excipients.
Skin in the game clauses for generic to take certain steps (or avoid certain dates) to maintain settlement stability.

What FDA status and labeling limitations shape adoption for Hedgehog pathway inhibitors?

Short answer: Label limitations and risk management drive real-world utilization more than theoretical efficacy. SMO inhibitors carry safety profiles requiring monitoring, and their indicated populations constrain the addressable market.

Key labeling constraints that affect commercial forecasts

Narrow tumor types and staging criteria (especially basal cell carcinoma subsections)
Treatment setting constraints (advanced/unresectable or metastatic)
Requirements around pregnancy prevention and fetal risk mitigation (class-level risk)

Pathway biology and resistance affect dosing continuity

Class relevance includes:

SMO pathway dependence for response
Potential resistance mechanisms that can reduce duration of therapy in practice

How does vismodegib compare with sonidegib on patent risk and likely generic launch timing?

Short answer: The practical difference is not efficacy but the structure of each estate: the number of Orange Book patents still in force near the same calendar window, the last-in-force patent category (compound vs polymorph vs method), and the presence of resolved litigation.

Side-by-side commercial risk framework (decision-useful)

If vismodegib’s last-in-force patents skew toward method-of-use and narrow formulation, generic substitution may remain limited until those claims expire or are settled.
If sonidegib’s latest listed patents skew toward broad compound/formulation, it can delay entry despite earlier-than-expected patent expiry of older families.

Competitive positioning under patent thinning

As each brand approaches expiry:

Switch demand can shift to the remaining protected SMO inhibitor,
Off-label or supportive care can increase,
Payers can tighten formulary preferences based on cost.

What formulation patents protect Hedgehog pathway inhibitors, and what are the common design-around barriers?

Short answer: The most actionable barriers for generic ANDA efforts are often formulation and solid-state patents. These can be difficult to design around without triggering infringement on polymorph-specific and excipient-specific claims.

Formulation patent themes

Specific tablet excipient blends
Granulation, compression, and processing parameter ranges
Controlled particle size specifications
Solid-state forms (polymorph/crystal) tied to stability and dissolution

Why these matter for ANDA timelines

Even when bioequivalence is achievable, infringement risk on a formulation or polymorph claim can stall approval or launch until litigation or settlement.

What method-of-use patents cover Hedgehog pathway inhibitors, and how do they affect generic substitution?

Short answer: Method-of-use patents can restrict “practicing” covered treatment regimens even if a generic product is approved. The brand’s ability to assert method patents can block or delay market entry through settlement leverage or design constraints.

Typical method-of-use scopes

Basal cell carcinoma treatment regimens
Patient stratification (advanced/unresectable or metastatic)
Timing (neoadjuvant/adjuvant) in specific protocols
Dose and treatment duration ranges

Practical enforcement effect

In the US, method patents can affect:

Generic launch decisions,
Off-label prescribing risk,
Settlement settlement terms that include training or labeling carve-outs.

Are there biosimilar risks for Hedgehog pathway inhibitors?

Short answer: No. Hedgehog pathway inhibitors in this class are predominantly small molecules (SMO inhibitors), so the biosimilar regulatory pathway is not the central threat mechanism.

What risk replaces biosimilars

ANDAs for small-molecule generics,
Compounding or parallel-import substitution in limited jurisdictions,
Reformulations that evade narrow formulation claims.

Which companies are positioned to challenge Hedgehog pathway inhibitor exclusivity?

Short answer: Generic challengers typically target the last-in-force patents via Paragraph IV and build launch readiness around settlement probability and design-around feasibility. The competitive set often includes multiple ANDA filers and generic portfolio companies active in oncology.

What determines challenger success probability

Whether they can design around polymorph/formulation claims,
Whether they can prevail in early validity disputes,
Whether brand settlements provide acceptable economics.

What global patent coverage exists for Hedgehog pathway inhibitors, and where is entry most likely?

Short answer: Global coverage is fragmented by jurisdiction. Entry probability is highest in jurisdictions where (1) formulation/polymorph enforcement is weaker, (2) patent enforcement timelines are slower, or (3) patent lists and litigation reach resolution sooner.

Jurisdiction-specific enforcement dynamics

US: Orange Book-driven ANDA entry and frequent Paragraph IV pressure points.
EU/UK: Patent litigation and SPCs can extend protection; generics depend on court timelines.
Other markets: enforcement and patent register fidelity can vary; local generic programs sometimes enter before US-style claim resolution.

Key Takeaways

Hedgehog pathway inhibitors are small-molecule SMO inhibitors whose market dynamics are dominated by layered patent estates: compound, polymorph/solid-state, formulation, and method-of-use.
Generic entry risk is driven by Orange Book coverage count and the last-in-force patent category, not by the earliest filing date alone.
Market exposure clusters near mid-to-late 2020s for major brands as last-in-force Orange Book patents approach expiry and Paragraph IV filings increase.
Formulation and polymorph patents are often the hardest design-around barriers, even when bioequivalence is feasible.
Biosimilar risk is not a primary issue for this class; ANDA and small-molecule generic substitution drive competition.

FAQs

1. What patents should be monitored first for Hedgehog pathway inhibitors during ANDA planning?
The last-in-force Orange Book patents by category: composition/formulation/polymorph and any method-of-use patents that remain active closest to the desired launch date.

2. Do hedgehog pathway inhibitor generic launches depend on settlement or on patent expiry?
Both. If the last-in-force patents are heavily asserted and settled, launch depends on settlement terms; otherwise it depends on the expiration and any remaining litigation or appeals.

3. How do polymorph and solid-state patents change the economics of generic development?
They increase development cost and time because the generic must control solid-state form and processing to avoid infringement or build a defensible non-infringing design.

4. Can a generic get FDA approval but still be blocked commercially by method-of-use patents?
Yes. FDA approval does not remove the risk of infringement for practicing covered treatment methods, which can pressure settlement and restrict market access.

5. What labeling and patient population factors most affect commercial value during patent thinning?
Indication scope, monitoring burdens, safety-driven discontinuation, and payer step-edits tied to prior SMO inhibitor exposure.

References

US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed via FDA Orange Book database).
FDA. Drug Approval Package for Erivedge (vismodegib) and Odomzo (sonidegib) (accessed via Drugs@FDA).
FDA. Labeling and risk management information for Hedgehog pathway inhibitors (accessed via product labeling on Drugs@FDA and FDA resources).